Risk factor
Low price volatility
Profitability factor
Very strong margins and returns
About
NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also...
Company Valuation
Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBIT
Target Price
The average target price of NATCOPHARM.NS is 957 and suggests 6% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation
Buy
Sell